Symbols / ARTL $6.61 -6.11% Artelo Biosciences, Inc.

Healthcare • Biotechnology • United States • NCM
ARTL Chart
About

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and insomnia, and other potential indications. It also offers ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Biotechnology Market Cap 5.40M
Enterprise Value 5.06M Income -12.88M Sales —
Book/sh -1.89 Cash/sh 0.85 Dividend Yield —
Payout 0.00% Employees 7 IPO —
P/E — Forward P/E -7.51 PEG —
P/S — P/B -3.50 P/C —
EV/EBITDA — EV/Sales — Quick Ratio 0.15
Current Ratio 0.17 Debt/Eq — LT Debt/Eq —
EPS (ttm) -37.56 EPS next Y -0.88 EPS Growth —
Revenue Growth — Earnings 2026-02-24 08:00 ROA -190.09%
ROE -16.25% ROIC — Gross Margin 0.00%
Oper. Margin 0.00% Profit Margin 0.00% Shs Outstand 817.13K
Shs Float 705.07K Short Float 5.29% Short Ratio 1.43
Short Interest — 52W High 85.80 52W Low 2.96
Beta 0.41 Avg Volume 2.86M Volume 177.26K
Target Price — Recom None Prev Close $7.04
Price $6.61 Change -6.11%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$6.63
Latest analyst target
3. DCF / Fair value
$-91.83
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$6.63
Low
—
High
—
Mean
—

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-11-19 down Maxim Group Buy → Hold —
2025-09-08 down D. Boral Capital Buy → Hold —
2025-08-26 main D. Boral Capital Buy → Buy $18
2025-08-18 main D. Boral Capital Buy → Buy $18
2025-08-06 main D. Boral Capital Buy → Buy $18
2025-08-04 main D. Boral Capital Buy → Buy $18
2025-07-08 up D. Boral Capital Hold → Buy $20
2025-06-11 down D. Boral Capital Buy → Hold —
2025-06-06 main D. Boral Capital Buy → Buy $6
2025-04-28 main D. Boral Capital Buy → Buy $6
2025-04-02 main D. Boral Capital Buy → Buy $6
2025-03-04 reit HC Wainwright & Co. Buy → Buy $5
2025-03-03 main D. Boral Capital Buy → Buy $6
2025-02-27 main D. Boral Capital Buy → Buy $6
2025-01-14 main D. Boral Capital Buy → Buy $6
2024-12-09 main D. Boral Capital Buy → Buy $6
2024-12-09 reit HC Wainwright & Co. Buy → Buy $5
2024-08-14 reit HC Wainwright & Co. Buy → Buy $5
2024-06-05 reit HC Wainwright & Co. Buy → Buy $5
2024-05-15 reit HC Wainwright & Co. Buy → Buy $5
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-10-28 MATSUI CONNIE L Director — 38,346 $3.55 $136,128
2025-10-28 GORGAS GREGORY D Chief Executive Officer — 9,586 $3.55 $34,030
2025-10-28 FAVORITO TAMARA A. Director — 6,846 $3.55 $24,303
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
11.40
+12.82%
10.11
+1.79%
9.93
-3.47%
10.29
Research And Development
5.42
-9.51%
5.99
+5.21%
5.70
+31.73%
4.32
Selling General And Administration
5.98
+45.35%
4.12
-2.81%
4.23
-29.00%
5.96
General And Administrative Expense
5.98
+45.35%
4.12
-2.81%
4.23
-29.00%
5.96
Other Gand A
5.98
+45.35%
4.12
-2.81%
4.23
-29.00%
5.96
Total Expenses
11.40
+12.82%
10.11
+1.79%
9.93
-3.47%
10.29
Operating Income
-11.40
-12.82%
-10.11
-1.79%
-9.93
+3.47%
-10.29
Total Operating Income As Reported
-11.40
-12.82%
-10.11
-1.79%
-9.93
+3.47%
-10.29
EBITDA
-12.60
-28.25%
-9.83
+1.05%
-9.93
+1.47%
-10.08
Normalized EBITDA
-11.40
-12.82%
-10.11
+4.38%
-10.57
-2.78%
-10.29
EBIT
-12.60
-28.25%
-9.83
+1.05%
-9.93
+1.47%
-10.08
Total Unusual Items
-1.20
-524.82%
0.28
-56.01%
0.64
+209.66%
0.21
Total Unusual Items Excluding Goodwill
-1.20
-524.82%
0.28
-56.01%
0.64
+209.66%
0.21
Special Income Charges
-1.16
0.00
—
—
Other Special Charges
1.16
—
—
—
Net Income
-12.88
-31.07%
-9.83
-5.78%
-9.29
+7.87%
-10.08
Pretax Income
-12.88
-31.07%
-9.83
-5.78%
-9.29
+7.87%
-10.08
Net Non Operating Interest Income Expense
-0.28
0.00
0.00
+100.00%
-0.00
Interest Expense Non Operating
0.28
0.00
0.00
-100.00%
0.01
Net Interest Income
-0.28
0.00
0.00
+100.00%
-0.00
Interest Expense
0.28
0.00
0.00
-100.00%
0.01
Interest Income Non Operating
—
—
0.00
-100.00%
0.00
Interest Income
—
—
0.00
-100.00%
0.00
Other Income Expense
-1.20
-524.82%
0.28
-56.01%
0.64
+209.66%
0.21
Gain On Sale Of Security
-0.04
-114.18%
0.28
-56.01%
0.64
+209.66%
0.21
Tax Provision
0.00
0.00
0.00
0.00
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-12.88
-31.07%
-9.83
-5.78%
-9.29
+7.87%
-10.08
Net Income From Continuing Operation Net Minority Interest
-12.88
-31.07%
-9.83
-5.78%
-9.29
+7.87%
-10.08
Net Income From Continuing And Discontinued Operation
-12.88
-31.07%
-9.83
-5.78%
-9.29
+7.87%
-10.08
Net Income Continuous Operations
-12.88
-31.07%
-9.83
-5.78%
-9.29
+7.87%
-10.08
Normalized Income
-11.68
-15.56%
-10.11
-1.79%
-9.93
+3.50%
-10.29
Net Income Common Stockholders
-12.88
-31.07%
-9.83
-5.78%
-9.29
+7.87%
-10.08
Diluted EPS
—
-54.90
+2.87%
-56.52
+11.80%
-64.08
Basic EPS
—
-54.90
+2.87%
-56.52
+11.80%
-64.08
Basic Average Shares
—
0.18
+8.85%
0.16
+4.48%
0.16
Diluted Average Shares
—
0.18
+8.85%
0.16
+4.48%
0.16
Diluted NI Availto Com Stockholders
-12.88
-31.07%
-9.83
-5.78%
-9.29
+7.87%
-10.08
Line Item Trend 2023-12-31
Total Assets
13.04
Current Assets
10.98
Cash Cash Equivalents And Short Term Investments
10.43
Cash And Cash Equivalents
2.81
Other Short Term Investments
7.61
Prepaid Assets
—
Other Current Assets
0.55
Total Non Current Assets
2.06
Net PPE
0.02
Gross PPE
0.02
Properties
0.00
Buildings And Improvements
0.02
Other Properties
0.02
Goodwill And Other Intangible Assets
2.04
Other Intangible Assets
2.04
Investments And Advances
—
Non Current Prepaid Assets
—
Other Non Current Assets
0.00
Total Liabilities Net Minority Interest
1.29
Current Liabilities
1.29
Payables And Accrued Expenses
1.27
Payables
1.27
Accounts Payable
1.24
Current Accrued Expenses
—
Current Debt And Capital Lease Obligation
0.02
Current Debt
—
Other Current Borrowings
—
Current Capital Lease Obligation
0.02
Other Current Liabilities
—
Total Non Current Liabilities Net Minority Interest
0.00
Long Term Debt And Capital Lease Obligation
0.00
Long Term Capital Lease Obligation
0.00
Stockholders Equity
11.75
Common Stock Equity
11.75
Capital Stock
0.00
Common Stock
0.00
Preferred Stock
0.00
Share Issued
0.18
Ordinary Shares Number
0.18
Treasury Shares Number
0.00
Additional Paid In Capital
52.26
Retained Earnings
-40.31
Gains Losses Not Affecting Retained Earnings
-0.20
Other Equity Adjustments
-0.20
Total Equity Gross Minority Interest
11.75
Total Capitalization
11.75
Working Capital
9.69
Invested Capital
11.75
Total Debt
0.02
Net Debt
—
Capital Lease Obligations
0.02
Net Tangible Assets
9.71
Tangible Book Value
9.71
Dueto Related Parties Current
0.03
Interest Payable
—
Investmentin Financial Assets
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-8.52
-2.04%
-8.35
-1.74%
-8.21
-2.49%
-8.01
Cash Flow From Continuing Operating Activities
-8.52
-2.04%
-8.35
-1.74%
-8.21
-2.49%
-8.01
Net Income From Continuing Operations
-12.88
-31.07%
-9.83
-5.78%
-9.29
+7.87%
-10.08
Other Non Cash Items
0.21
+6833.33%
0.00
—
-0.00
Stock Based Compensation
1.14
+39.61%
0.82
-19.80%
1.02
-58.50%
2.46
Operating Gains Losses
1.22
—
—
—
Gain Loss On Investment Securities
0.06
—
—
—
Unrealized Gain Loss On Investment Securities
0.00
+100.00%
-0.28
+56.01%
-0.64
-209.66%
-0.21
Change In Working Capital
1.79
+90.93%
0.94
+33.29%
0.70
+508.72%
-0.17
Change In Prepaid Assets
0.13
-71.77%
0.46
+6.28%
0.43
+320.51%
-0.20
Change In Payables And Accrued Expense
1.66
+245.83%
0.48
+75.82%
0.27
+1086.96%
0.02
Change In Accrued Expense
0.07
0.00
—
—
Change In Payable
1.59
+231.46%
0.48
+75.82%
0.27
+1086.96%
0.02
Change In Account Payable
1.59
+231.46%
0.48
+75.82%
0.27
+1086.96%
0.02
Investing Cash Flow
-0.06
-100.80%
7.77
+121.53%
3.51
+18.56%
2.96
Cash Flow From Continuing Investing Activities
-0.06
-100.80%
7.77
+121.53%
3.51
+18.56%
2.96
Net Investment Purchase And Sale
-0.06
-100.80%
7.77
+121.53%
3.51
+18.56%
2.96
Purchase Of Investment
-0.25
+48.02%
-0.48
+96.49%
-13.69
-3.49%
-13.22
Sale Of Investment
0.19
-97.72%
8.25
-52.01%
17.19
+6.24%
16.18
Financing Cash Flow
6.87
+6031.25%
0.11
-80.25%
0.57
0.00
Cash Flow From Continuing Financing Activities
6.87
+6031.25%
0.11
-80.25%
0.57
0.00
Net Issuance Payments Of Debt
0.58
0.00
—
—
Issuance Of Debt
0.61
0.00
—
—
Repayment Of Debt
-0.02
0.00
—
—
Short Term Debt Issuance
0.61
0.00
—
—
Short Term Debt Payments
-0.02
0.00
—
—
Net Short Term Debt Issuance
0.58
0.00
—
—
Net Common Stock Issuance
6.15
+5391.96%
0.11
-80.25%
0.57
0.00
Proceeds From Stock Option Exercised
0.13
0.00
—
0.00
Net Other Financing Charges
—
—
—
—
Changes In Cash
-1.72
-265.67%
-0.47
+88.65%
-4.13
+18.16%
-5.05
Effect Of Exchange Rate Changes
-0.02
-187.50%
-0.01
-113.33%
0.06
+126.79%
-0.22
Beginning Cash Position
2.34
-16.94%
2.81
-59.13%
6.89
-43.36%
12.16
End Cash Position
0.60
-74.34%
2.34
-16.94%
2.81
-59.13%
6.89
Free Cash Flow
-8.52
-2.04%
-8.35
-1.74%
-8.21
-2.49%
-8.01
Interest Paid Supplemental Data
0.00
0.00
0.00
0.00
Income Tax Paid Supplemental Data
0.00
0.00
0.00
0.00
Change In Interest Payable
0.07
0.00
—
—
Common Stock Issuance
6.15
+5391.96%
0.11
-80.25%
0.57
0.00
Issuance Of Capital Stock
6.15
+5391.96%
0.11
-80.25%
0.57
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category